PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance

Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments

(2022) Shogo Kumagai et al.   CANCER CELL

PD-L1–PD-1 interactions limit effector regulatory T cell populations at homeostasis and during infection

(2022) Joseph A. Perry et al.   NATURE IMMUNOLOGY

Regulatory T Cell Depletion Using a CRISPR Fc-Optimized CD25 Antibody

(2022) Marit J. van Elsas et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

BATF epigenetically and transcriptionally controls the activation program of regulatory T cells in human tumors

(2022) Kota Itahashi et al.   Science Immunology

Metabolic support of tumour-infiltrating regulatory T cells by lactic acid

(2021) McLane J. Watson et al.   NATURE

Lipid signalling enforces functional specialization of Treg cells in tumours

(2021) Seon Ah Lim et al.   NATURE

Anti–PD-1 Checkpoint Therapy Can Promote the Function and Survival of Regulatory T Cells

(2021) Sarah C. Vick et al.   JOURNAL OF IMMUNOLOGY

CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors

(2020) Haiping Wang et al.   NATURE IMMUNOLOGY

Targeted deletion of PD-1 in myeloid cells induces antitumor immunity

(2020) Laura Strauss et al.   Science Immunology

Targeting Endoglin-Expressing Regulatory T Cells in the Tumor Microenvironment Enhances the Effect of PD1 Checkpoint Inhibitor Immunotherapy

(2020) Mark J.A. Schoonderwoerd et al.   CLINICAL CANCER RESEARCH

Novel, Non–Gene-Destructive Knock-In Reporter Mice Refute the Concept of Monoallelic Gata3 Expression

(2020) Tata Nageswara Rao et al.   JOURNAL OF IMMUNOLOGY

Future Challenges in Cancer Resistance to Immunotherapy

(2020) Marit J. van Elsas et al.   Cancers

Tumor invasion in draining lymph nodes is associated with Treg accumulation in breast cancer patients

(2020) Nicolas Gonzalo Núñez et al.   Nature Communications

The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes

(2020) Floris Dammeijer et al.   CANCER CELL

PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance

(2020) Catherine L. Tan et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies

(2020) Shogo Kumagai et al.   NATURE IMMUNOLOGY

Regulatory T cells in cancer immunosuppression — implications for anticancer therapy

(2019) Yosuke Togashi et al.   Nature Reviews Clinical Oncology

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

(2019) J Mazières et al.   ANNALS OF ONCOLOGY

PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer

(2019) Takahiro Kamada et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Clonal replacement of tumor-specific T cells following PD-1 blockade

(2019) Kathryn E. Yost et al.   NATURE MEDICINE

Metascape provides a biologist-oriented resource for the analysis of systems-level datasets

(2019) Yingyao Zhou et al.   Nature Communications

DEsingle for detecting three types of differential expression in single-cell RNA-seq data

(2018) Zhun Miao et al.   BIOINFORMATICS

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

Accurate quantification of T-cells expressing PD-1 in patients on anti-PD-1 immunotherapy

(2018) Henning Zelba et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

(2018) Leora Horn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma

(2018) Hanjie Li et al.   CELL

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma

(2018) Moshe Sade-Feldman et al.   CELL

Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors

(2017) Frederick Arce Vargas et al.   IMMUNITY

Monitoring immune-checkpoint blockade: response evaluation and biomarker development

(2017) Mizuki Nishino et al.   Nature Reviews Clinical Oncology

Tumor Mutational Burden and Response Rate to PD-1 Inhibition

(2017) Mark Yarchoan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy

(2017) Floris Dammeijer et al.   Cancer Immunology Research

Assessing Immune-Related Adverse Events of Efficacious Combination Immunotherapies in Preclinical Models of Cancer

(2016) Jing Liu et al.   CANCER RESEARCH

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis

(2016) J. F. Gainor et al.   CLINICAL CANCER RESEARCH

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

(2016) Scott J Antonia et al.   LANCET ONCOLOGY

Nonoverlapping roles of PD-1 and FoxP3 in maintaining immune tolerance in a novel autoimmune pancreatitis mouse model

(2016) Baihao Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

HISAT: a fast spliced aligner with low memory requirements

(2015) Daehwan Kim et al.   NATURE METHODS

Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis

(2015) Bin Shang et al.   Scientific Reports

Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection

(2014) Pablo Penaloza-MacMaster et al.   JOURNAL OF EXPERIMENTAL MEDICINE

TSC1 regulates the balance between effector and regulatory T cells

(2013) Yoon Park et al.   JOURNAL OF CLINICAL INVESTIGATION

A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application

(2013) Taku Okazaki et al.   NATURE IMMUNOLOGY

Smart-seq2 for sensitive full-length transcriptome profiling in single cells

(2013) Simone Picelli et al.   NATURE METHODS

Suppression assays with human T regulatory cells: A technical guide

(2011) Alicia N. McMurchy et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

A Practical Guide of the Southwest Oncology Group to Measure Malignant Pleural Mesothelioma Tumors by RECIST and Modified RECIST Criteria

(2011) Anne S. Tsao et al.   Journal of Thoracic Oncology

The Ets-1 transcription factor controls the development and function of natural regulatory T cells

(2010) Enguerran Mouly et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Methylation matters: binding of Ets-1 to the demethylated Foxp3 gene contributes to the stabilization of Foxp3 expression in regulatory T cells

(2010) Julia K. Polansky et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Simple Combinations of Lineage-Determining Transcription Factors Prime cis-Regulatory Elements Required for Macrophage and B Cell Identities

(2010) Sven Heinz et al.   MOLECULAR CELL

PD-1 signaling in primary T cells

(2009) James L. Riley   IMMUNOLOGICAL REVIEWS

CTLA-4 Control over Foxp3+ Regulatory T Cell Function

(2008) K. Wing et al.   SCIENCE